Treats postmenopausal women or adult men with estrogen … metastatic breast cancer. Sold as Orserdu. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Elacestrant Hydrochloride (sold as Orserdu), first approved Jan 27, 2023, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Orserdu | Part D | $387M | +49% | 3,542 |
| Ph 2 Elacestrant in ER Positive Uterine SarcomasUterine Sarcoma, Uterine Leiomyosarcoma · Dana-Farber Cancer Institute | Phase 2 | Recruiting | Mar 12, 2026 |
| PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer · Kristina A. Fanucci | Phase 2 | Recruiting | Oct 29, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jan 27, 2023 | OrserduNDA 217639 · New molecular entity | Stemline Therap | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA